Bioceres Crop Solutions Corp
Bioceres Crop Solutions Corp develops and commercializes biological crop protection and enhancement solutions, primarily targeting the agricultural sector.
Business. Bioceres Crop Solutions Corp (BIOX.O) is an agricultural chemicals company operating within the Basic Materials sector. The firm is headquartered in Argentina and primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bioceres Crop Solutions Corp (BIOX.O) is an agricultural chemicals company operating within the Basic Materials sector. The firm is headquartered in Argentina and primarily listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.
Bioceres operates with a market cap of $28.7 million and a price-to-book ratio of 0.09, indicating a significant discount to its book value. The company's liquidity position is characterized by $16.4 million in cash and equivalents, but its long-term debt of $255.1 million creates a debt-to-equity ratio of 0.81, suggesting moderate leverage. The current ratio of 1.22 indicates the company can cover its short-term liabilities with its current assets, but the margin is narrow.
Profitability metrics show a return on equity of 2.95% and a return on assets of 1.11%, both below the industry median for Agricultural Chemicals. The company's net income of $9.3 million on $84 million in revenue yields a net margin of 11%, which is in line with the industry median but not exceptional. Gross profit of $42.7 million on $84 million in revenue results in a gross margin of 50.8%, which is strong and suggests efficient cost management.
Geographically, Bioceres' revenue is concentrated in a few key markets, with the Americas accounting for the majority of its sales. The company has not disclosed specific segment breakdowns, but its exposure to the agricultural sector makes it sensitive to commodity price fluctuations and regulatory changes in agrochemicals. The company's capital expenditures of -$16.7 million suggest a reduction in investment in physical assets, which may reflect a strategic shift or financial constraints.
Looking ahead, the company is expected to report a net loss of $0.16 per share in the current fiscal year, a significant improvement from the $0.82 loss in the previous year. However, the mean analyst recommendation of 3.00 (Hold) suggests limited upside potential in the near term. The company's free cash flow of $8.7 million indicates some capacity to fund operations or reduce debt, but the negative net cash position after subtracting total debt raises concerns about long-term liquidity.
The risk assessment highlights a medium liquidity risk due to the company's negative net cash position after subtracting total debt. The dilution risk is rated as low, with no significant dilution expected in the near term. The company's capital structure and financial flexibility are constrained by its high debt load, which could limit its ability to invest in growth opportunities.
Recent filings and transcripts indicate that the company is focused on expanding its product portfolio and entering new markets. However, the lack of strong buy recommendations from analysts and the current market price of $0.4494 suggest that investor sentiment remains cautious. The company's recent performance and strategic direction will be critical in determining its future trajectory.
- Bioceres trades at a significant discount to book value, with a price-to-book ratio of 0.09.
- The company's gross margin of 50.8% is strong, but its return on equity of 2.95% is below the industry median.
- The company's liquidity position is constrained by a negative net cash position after subtracting total debt.
- Analysts have a neutral outlook, with a mean recommendation of 3.00 (Hold).
- The company's free cash flow of $8.7 million provides some financial flexibility but is insufficient to cover its debt load.
- The company's strategic focus on expanding its product portfolio and entering new markets may drive future growth.
Bull / Bear case
Generated · model-assistedNet margin of 11.0% ranks above the 75th percentile of the 139-company Agricultural Chemicals cohort benchmark.
Revenue grew at a 12.7% compound annual growth rate over the four-year period ending in fiscal 2025.
Cash conversion ratio of 1.99 is more than double the 0.9 cohort median, suggesting strong cash generation relative to earnings.
Gross profit reached $129.9 million in fiscal 2025, maintaining a robust margin despite significant revenue contraction.
The company carries a high credit risk flag, compounded by long-term debt increasing to $276.6 million in fiscal 2025.
In focus — financials by report
Revenue $73.7M, −25,5% YoY; Operating income −47,6% YoY.
- ▍Revenue $73.7M, −25,5% YoY
- ▍Operating income −47,6% YoY
- ▍Net income −127 618,3% YoY
- ▍Free cash flow −130,0% YoY
- ▍Net margin -248.4%
Revenue $77.4M, −16,4% YoY; Operating income +204,3% YoY.
- ▍Revenue $77.4M, −16,4% YoY
- ▍Operating income +204,3% YoY
- ▍Net income −15,1% YoY
- ▍Free cash flow +25,8% YoY
- ▍Net margin -9.5%
Revenue $74.4M, −40,2% YoY; Operating income −228,0% YoY.
- ▍Revenue $74.4M, −40,2% YoY
- ▍Operating income −228,0% YoY
- ▍Net income −9 509,0% YoY
- ▍Free cash flow −9 825,5% YoY
- ▍Net margin -64.4%
Revenue $59.6M, −29,1% YoY; Operating income −92,9% YoY.
- ▍Revenue $59.6M, −29,1% YoY
- ▍Operating income −92,9% YoY
- ▍Net income −114,1% YoY
- ▍Free cash flow −85,1% YoY
- ▍Net margin -2.2%
Revenue $98.9M; Operating income $14.4M.
- ▍Revenue $98.9M
- ▍Operating income $14.4M
- ▍Net margin 0.1%
Revenue $92.6M; Operating income $2.4M.
- ▍Revenue $92.6M
- ▍Operating income $2.4M
- ▍Net margin -6.9%
Revenue $124.3M; Operating income $10.5M.
- ▍Revenue $124.3M
- ▍Operating income $10.5M
- ▍Net margin -0.4%
Revenue $84.0M; Operating income $13.2M.
- ▍Revenue $84.0M
- ▍Operating income $13.2M
- ▍Net margin 11.0%
Revenue $333.3M, −28,3% YoY; Operating income −104,9% YoY.
- ▍Revenue $333.3M, −28,3% YoY
- ▍Operating income −104,9% YoY
- ▍Net income −1 396,1% YoY
- ▍Free cash flow −1 012,4% YoY
- ▍Net margin -16.6%
Revenue $464.8M, +12,0% YoY; Operating income −15,4% YoY.
- ▍Revenue $464.8M, +12,0% YoY
- ▍Operating income −15,4% YoY
- ▍Net income −77,2% YoY
- ▍Free cash flow −66,0% YoY
- ▍Net margin 0.9%
Revenue $415.1M, +26,4% YoY; Operating income +35,9% YoY.
- ▍Revenue $415.1M, +26,4% YoY
- ▍Operating income +35,9% YoY
- ▍Net income +360,9% YoY
- ▍Free cash flow +545,1% YoY
- ▍Net margin 4.5%
Revenue $328.4M, +58,9% YoY; Operating income +3,9% YoY.
- ▍Revenue $328.4M, +58,9% YoY
- ▍Operating income +3,9% YoY
- ▍Net income −4,8% YoY
- ▍Free cash flow +67,6% YoY
- ▍Net margin -2.2%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,16 |
| Revenue | —no estimate | —no estimate | 307,1M USD |
| Operating income | —no estimate | —no estimate | 21,9M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Bioceres Crop Solutions Corp Market data — financials · 2026-05-27
- Bioceres Crop Solutions Corp Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Federico TruccoChief Executive Officer, Executive Director